Edition:
India

Sino Biopharmaceutical Ltd (1177.HK)

1177.HK on Hong Kong Stock

10.82HKD
7:38am IST
Change (% chg)

HK$0.02 (+0.19%)
Prev Close
HK$10.80
Open
HK$10.90
Day's High
HK$11.04
Day's Low
HK$10.74
Volume
12,648,900
Avg. Vol
53,227,814
52-wk High
HK$12.24
52-wk Low
HK$4.53

Latest Key Developments (Source: Significant Developments)

Sino Biopharmaceutical Says Unit's "Apixaban Tablet" Got Drug Registration Approval In PRC
Wednesday, 22 May 2019 

May 22 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::UNIT'S APIXABAN TABLET GETS APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says "Gefitinib Tablet" Obtained Approval For Drug Registration
Monday, 20 May 2019 

May 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::"GEFITINIB TABLET" OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF CHINA.  Full Article

Sino Biopharmaceutical Says Unit Gets Approval For Generic Drugs
Wednesday, 24 Apr 2019 

April 24 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC APPROVED CONSISTENCY OF QUALITY & EFFICACY EVALUATION FOR GENERIC DRUGS OF UNIT.  Full Article

Sino Biopharmaceutical, As Borrower, Enters Facility Agreement
Wednesday, 10 Apr 2019 

April 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::CO AS BORROWER ENTERED A FACILITY AGREEMENT FOR A TERM LOAN FACILITY IN AGGREGATE PRINCIPAL AMOUNT US$1.0 BILLION.  Full Article

Sino Biopharmaceutical Says Profit Of Group For Year Is Expected To Increase Significantly
Wednesday, 20 Mar 2019 

March 20 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::PROFIT OF GROUP FOR YEAR IS EXPECTED TO INCREASE SIGNIFICANTLY.PROFIT ATTRIBUTABLE FOR YEAR EXPECTED TO INCREASE TO A RANGE OF ABOUT RMB8,908.37 MILLION TO ABOUT RMB9,283.71 MILLION.EXPECTED RESULT DUE TO CERTAIN PROFIT OR LOSS ITEMS THAT ARE REQUIRED TO BE RECOGNIZED IN ACCOUNTS OF CO.  Full Article

Sino Biopharmaceutical Says Anti-Tumor Drug Lenalidomide Capsule Gets Approval For Drug Registration
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::ANTI-TUMOR DRUG LENALIDOMIDE CAPSULE DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA IN CHINA.  Full Article

Sino Biopharmaceutical Says Parecoxib Sodium For Injection Obtained Approval For Drug Registration
Monday, 10 Dec 2018 

Dec 10 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::PARECOXIB SODIUM FOR INJECTION OBTAINED APPROVAL FOR DRUG REGISTRATION BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC.  Full Article

Sino Biopharmaceutical Says Parecoxib Sodium For Injection Gets Approval For Drug Registration
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::SINO BIOPHARMACEUTICAL SAYS PARECOXIB SODIUM FOR INJECTION DEVELOPED BY UNIT GETS APPROVAL FOR DRUG REGISTRATION BY NMPA.  Full Article

Sino Biopharmaceutical Posts 9-Mth Revenue Of RMB15,730.16 Mln, Up 37.4 Pct
Thursday, 22 Nov 2018 

Nov 22 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::9-MONTH REVENUE RMB15,730.16 MILLION, UP 37.4 PERCENT.DECLARED PAYMENT OF A THIRD QUARTERLY DIVIDEND OF HK2 CENTS PER SHARE.9-MONTH PROFIT ATTRIBUTABLE RMB2,201.26 MILLION, UP 22.0%.  Full Article

Sino Biopharmaceutical Says Unit's Product Obtains Approval For Drug Registration
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - Sino Biopharmaceutical Ltd <1177.HK>::MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION OBTAINS APPROVAL FOR DRUG REGISTRATION.APPROVAL GRANTED BY NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PEOPLE'S REPUBLIC OF CHINA.  Full Article